PTC-028

A novel potent, selective, orally bioavailable BMI-1 inhibitor with potent anti-MM activity against primary MM cells (IC50=10-100 nM); decreases BMI-1 levels by posttranslational modification, selectively inhibits cancer cells in clonal growth and viability assays (IC50=100 nM), without effeccts on normal cells; exhibits significant antitumor activity in mouse model of ovarian cancer.